Sanofi’s Hematology Push in China: Qfitlia and Cablivi Approved — Fifth Sanofi Nod in 2025
Sanofi announced Chinese approvals for Qfitlia (fitusiran) and Cablivi (caplacizumab), expanding its rare-hematology portfolio and bringing the company’s total Chinese approvals this year to five. Read the implications for patients and the market.
387 views
•
5 months ago